中国组织工程研究

中国组织工程研究 ›› 2010, Vol. 14 ›› Issue (18): 3271-3274.doi: 10.3969/j.issn.1673-8225.2010.18.010

• 肾移植 kidney transplantation • 上一篇    下一篇

电切术后黏膜下注射表柔比星治疗肾移植受者膀胱移行细胞癌复发：安全及有效?

张  勇，王  勇，张小东，李晓北，杨  勇   

  1. 首都医科大学附属北京朝阳医院泌尿外科，北京市     100020
  • 出版日期:2010-04-30 发布日期:2010-04-30
  • 作者简介:张 勇☆，男，1972年生，河北省南宫县人，汉族，2008年首都医科大学毕业，博士，副主任医师，副教授，硕士生导师，主要从事肾移植和泌尿外科方面的研究。 doctorzhy@126.com

Treatment of bladder transitional cell carcinoma recurrence by transurethral resection followed by submucosal injection Epirubicin in renal transplantation recipients: Is it safe and effective?

Zhang Yong, Wang Yong, Zhang Xiao-dong, Li Xiao-bei, Yang Yong   

  1. Department of Urology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing  100020, China
  • Online:2010-04-30 Published:2010-04-30
  • About author:Zhang Yong☆, Doctor, Associate chief physician, Associate professor, Master’s supervisor, Department of Urology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China doctorzhy@126.com

PDF

400

摘要：

背景：肾移植受者处于低免疫状态，与普通人群相比，发生的膀胱移行细胞癌进展快、易复发。寻找更有效的治疗方法降低肾移植受者膀胱移行细胞癌复发是临床研究的热点和难点。
目的：验证经尿道膀胱肿瘤电切术后膀胱黏膜下注射表柔比星治疗肾移植受者膀胱移行细胞癌的有效性和安全性。
方法：用自身对照法回顾9例合并膀胱移行细胞癌的肾移植受者的病例资料，对比分析不同时期分别采用羟基喜树碱或丝裂霉素常规灌注和膀胱黏膜下注射表柔比星时，患者的无瘤间期、肿瘤复发次数、不良反应发生率、膀胱肿瘤复发时分级分期变化和移植肾功能等。
结果与结论：使用经尿道膀胱肿瘤电切术后膀胱黏膜下注射表柔比星治疗易复发、相对难治的肾移植受者膀胱移行细胞癌有效、安全，与常规灌注相比，患者无瘤间期明显延长，1年内复发次数明显减少，可提高肾移植患者生活质量和移植肾长期存活率。

关键词: 表柔比星, 膀胱癌, 肾移植, 肿瘤复发, 经尿道膀胱肿瘤电切

Abstract:

BACKGROUND: The renal transplanted recipients were in poor immunosuppressive state. Compared to common person, the bladder transitional carcinoma in recipients was aggressive and easy to recurrence. Looking for a more effective therapy method to decrease the recurrence of recipients’ bladder transitional carcinoma is the hot and difficult problem in clinical study.
OBJECTIVE: To analyze the efficacy and safety of submucosal injection epirubicin following transurethral resection of bladder tumor (TUR-Bt) to treat the recurrence of bladder transitional cell carcinoma in renal transplantation recipients.
METHODS: Totally 9 renal transplantation recipients with transitional cell carcinoma of bladder were retrospectively studied. The patients’ periods without cancer, the frequency of recurrence within one year, the rates of side effect, the changes of tumor grading following recurrence and allograft function were recorded when the routine method and submucosal injection epirubicin following TUR-Bt were used in different period respectively. 
RESULTS AND CONCLUSION: Submucosal injection epirubicin following transurethral resection of bladder tumor was safe and effective to treat bladder transitional cell carcinoma recurrence in renal transplantation recipients. Compared to the routine perfusion, periods without cancer and the frequency of recurrence within 1 year were significantly decreased, which can elevate recipients life quality and long-term survival rates.

中图分类号: